Vident Advisory LLC Makes New Investment in Amicus Therapeutics, Inc. $FOLD

Vident Advisory LLC bought a new position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 12,457 shares of the biopharmaceutical company’s stock, valued at approximately $102,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC boosted its position in Amicus Therapeutics by 53.7% during the first quarter. Allspring Global Investments Holdings LLC now owns 24,530 shares of the biopharmaceutical company’s stock worth $195,000 after purchasing an additional 8,567 shares during the period. Jefferies Financial Group Inc. bought a new position in Amicus Therapeutics during the first quarter worth about $1,533,000. Rice Hall James & Associates LLC boosted its position in shares of Amicus Therapeutics by 46.6% in the first quarter. Rice Hall James & Associates LLC now owns 2,010,104 shares of the biopharmaceutical company’s stock valued at $16,402,000 after acquiring an additional 639,024 shares during the period. Invesco Ltd. boosted its position in shares of Amicus Therapeutics by 4.1% in the first quarter. Invesco Ltd. now owns 2,661,394 shares of the biopharmaceutical company’s stock valued at $21,717,000 after acquiring an additional 105,856 shares during the period. Finally, Victory Capital Management Inc. boosted its position in shares of Amicus Therapeutics by 47.4% in the first quarter. Victory Capital Management Inc. now owns 257,088 shares of the biopharmaceutical company’s stock valued at $2,098,000 after acquiring an additional 82,691 shares during the period.

Amicus Therapeutics Price Performance

FOLD opened at $7.94 on Thursday. The stock has a 50-day moving average price of $6.87 and a 200-day moving average price of $7.03. Amicus Therapeutics, Inc. has a 12-month low of $5.51 and a 12-month high of $12.65. The company has a current ratio of 3.21, a quick ratio of 2.29 and a debt-to-equity ratio of 1.92. The stock has a market capitalization of $2.45 billion, a P/E ratio of -66.16 and a beta of 0.55.

Analysts Set New Price Targets

A number of research firms have recently commented on FOLD. Wall Street Zen lowered shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, August 30th. Morgan Stanley upgraded shares of Amicus Therapeutics from an “equal weight” rating to an “overweight” rating in a research report on Thursday, July 17th. Seven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $16.00.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.